NCT04533399 - A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults | Biotech Hunter

Enrollment

4,422

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

December 7, 2021

Study Completion Date

January 19, 2022

Conditions

SARS-CoV-2 InfectionCOVID-19

Interventions

BIOLOGICAL

SARS-CoV-2 rS/Matrix-M1 Adjuvant

Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.

OTHER

Placebo

Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.

Trial Locations (14)

ZA018, Bloemfontein

ZA003, Hillbrow

Site ZA001, Johannesburg

ZA012, Johannesburg

Site ZA015, Pretoria

ZA023, Pretoria

ZA019, Durban

ZA020, Durban

ZA021, Durban

ZA024, Durban

ZA007, Thabazimbi

ZA022, Madibeng

ZA013, Cape Town

ZA014, Worcester